Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: Jerry Olson who wrote (678)	3/23/1998 9:27:00 AM
From: Dennis	Read Replies (3) \| Respond to of 9523

So do I get filled at 92 3/4 or not????????????

To: Jerry Olson who wrote (678)	3/23/1998 9:39:00 AM
From: Wally Mastroly	Read Replies (1) \| Respond to of 9523

More PFE headlines -from Barrons' interview: biz.yahoo.com

To: Jerry Olson who wrote (678)	3/23/1998 3:23:00 PM
From: Ms. X	Respond to of 9523

(DJ) Technical Analyst sees Pfizer shares at $120 on New Drug New York (Dow Jones) Pfizer Inc.'s new impotence drug could boost its stock price to more than 120, Tom Dorsey, partner and technical analyst with Dorsey Wright & Associates, said during an appearance on CNBC Friday... Pfizer plans to put its new impotence pill on the market during the second quarter, pending food and drug administration approval, a company spokesman said. Last year the FDA put the drug, known as Viagra, on fast-track review, committing itself to act on the application within six months. That time-frame ends at the end of this month. In addition to Pfizer, Dorsey named Chevron Corp. and Mcdonalds.